BiVictriX Therapeutics PLC
LSE:BVX

Watchlist Manager
BiVictriX Therapeutics PLC Logo
BiVictriX Therapeutics PLC
LSE:BVX
Watchlist
Price: 10 GBX 17.65% Market Closed
Market Cap: 8.3m GBX

BiVictriX Therapeutics PLC
Operating Income

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

BiVictriX Therapeutics PLC
Operating Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Operating Income CAGR 3Y CAGR 5Y CAGR 10Y
BiVictriX Therapeutics PLC
LSE:BVX
Operating Income
-ÂŁ3m
CAGR 3-Years
-83%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Centessa Pharmaceuticals PLC
NASDAQ:CNTA
Operating Income
-$201.1m
CAGR 3-Years
-9%
CAGR 5-Years
-109%
CAGR 10-Years
N/A
Autolus Therapeutics PLC
NASDAQ:AUTL
Operating Income
-$273.9m
CAGR 3-Years
-15%
CAGR 5-Years
-11%
CAGR 10-Years
N/A
Immunocore Holdings PLC
NASDAQ:IMCR
Operating Income
-ÂŁ70.5m
CAGR 3-Years
18%
CAGR 5-Years
10%
CAGR 10-Years
N/A
Genus PLC
LSE:GNS
Operating Income
ÂŁ68.6m
CAGR 3-Years
6%
CAGR 5-Years
8%
CAGR 10-Years
6%
Oxford BioMedica PLC
LSE:OXB
Operating Income
-ÂŁ30.7m
CAGR 3-Years
-20%
CAGR 5-Years
-19%
CAGR 10-Years
-9%
No Stocks Found

BiVictriX Therapeutics PLC
Glance View

Market Cap
8.3m GBX
Industry
Biotechnology

BiVictriX Therapeutics Plc focuses on developing novel, highly-selective, bispecific ADCs to target unmet need in blood cancer. The company is headquartered in Alderley Edge, Cheshire and currently employs 5 full-time employees. The company went IPO on 2021-08-11. The firm has developed Bi-Cygni technology, which focuses on an area of unmet medical need. The firm utilizes Bi-Cygni therapeutics, which are designed to selectively target antigen co-expression fingerprints, or twin antigens, on tumour cells, which are absent from healthy cells. The firm has developed Bi-Cygni technology which utilizes Antibody Drug Conjugates, an existing class of potent biological drugs, for the treatment of various cancers including Acute Myeloid Leukaemia. The Company’s Bi-Cygni product candidate, BVX001, which is in early stage development for the treatment of acute myeloid leukaemia (AML). The firm has a diverse panel of cancer-specific twin antigens, across a range of cancer indications that include Diffuse Large B Cell Lymphoma, Acute Myeloid Leukaemia and Blastic Plasmacytoid Dendritic Cell Neoplasm.

BVX Intrinsic Value
Not Available

See Also

What is BiVictriX Therapeutics PLC's Operating Income?
Operating Income
-3m GBP

Based on the financial report for Dec 31, 2023, BiVictriX Therapeutics PLC's Operating Income amounts to -3m GBP.

What is BiVictriX Therapeutics PLC's Operating Income growth rate?
Operating Income CAGR 3Y
-83%

Over the last year, the Operating Income growth was -2%. The average annual Operating Income growth rates for BiVictriX Therapeutics PLC have been -83% over the past three years .

Back to Top